# Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing

> **NCT07743086** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 886 (estimated)

## Conditions studied

- Solid Tumor Cancer

## Interventions

- **DRUG:** Standard of Care chemotherapy Following an Algorithm
- **DRUG:** Standard of Care chemotherapy following CTCAE criteria

## Key facts

- **NCT ID:** NCT07743086
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 886 (ESTIMATED)
- **Last updated:** 2026-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743086, "Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*